Literature DB >> 15812625

Blockade of nuclear factor-kappaB activation prevents hypodynamic shock and gastric hypoperfusion induced by endotoxin in anesthetized dogs.

Chieko Mitaka1, Yukio Hirata, Yutaka Narumi, Kuninori Yokoyama, Koshi Makita, Koichi Katsuyama, Takasuke Imai.   

Abstract

OBJECTIVE: To investigate whether pyrrolidinone derivative (N2733), an inhibitor of nuclear factor (NF)-kappaB activation, improves altered metabolic and hemodynamic changes and organ dysfunctions caused by endotoxic shock. DESIGN AND
SETTING: Prospective, randomized, animal study in a laboratory at a university hospital.
SUBJECTS: Twenty-three anesthetized male beagle dogs (10-14 kg).
INTERVENTIONS: Dogs were mechanically ventilated and monitored with a pulmonary arterial catheter and a gastric tonometer. A central venous catheter was inserted into the femoral vein, and lactated Ringer's solution (10 ml/kg per hour) was administered throughout the study period. Three groups of animals were studied: (a) the lipopolysaccharide (LPS) group (n=8), which received LPS (250 ng/kg per minute for 2 h); (b) the LPS plus N2733 group (n=8), which received N2733 (30 mg/kg intravenously and 10 mg/kg hour for 6 h) after the start of LPS; and (c) the N2733 group (n=7), which received N2733 (30 mg/kg intravenously and 10 mg/kg per hour for 6 h). MEASUREMENTS AND
RESULTS: Changes in hemodynamics, blood gas, gastric intramural pH, and renal and hepatic function were measured for 6 h. Coadministration of N2733 increased oxygen delivery index and prevented the LPS-induced hypotension, metabolic acidosis, and gastric mucosal acidosis but did not affect renal or hepatic function.
CONCLUSIONS: Administration of N2733 increased oxygen delivery index and prevented the LPS-induced hypotension and metabolic and gastric mucosal acidosis in an anesthetized canine endotoxic shock model, suggesting its beneficial effect on local blood flow against tissue hypoxia. These findings suggest that blockade of NF-kappaB activation prevents hypodynamic shock and gastric hypoperfusin in endotoxic shock.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15812625     DOI: 10.1007/s00134-005-2617-1

Source DB:  PubMed          Journal:  Intensive Care Med        ISSN: 0342-4642            Impact factor:   17.440


  21 in total

1.  A pyrrolidinone derivative inhibits cytokine-induced iNOS expression and NF-kappaB activation by preventing phosphorylation and degradation of IkappaB-alpha.

Authors:  K Katsuyama; Y Hirata
Journal:  J Biochem       Date:  2001-04       Impact factor: 3.387

2.  Role of NFkappaB in the mortality of sepsis.

Authors:  H Böhrer; F Qiu; T Zimmermann; Y Zhang; T Jllmer; D Männel; B W Böttiger; D M Stern; R Waldherr; H D Saeger; R Ziegler; A Bierhaus; E Martin; P P Nawroth
Journal:  J Clin Invest       Date:  1997-09-01       Impact factor: 14.808

Review 3.  NF-kappaB in critical diseases: a bad guy?

Authors:  Uwe Senftleben
Journal:  Intensive Care Med       Date:  2003-09-04       Impact factor: 17.440

4.  Interleukin-1 contributes to the induction of nitric oxide synthase by endotoxin in vivo.

Authors:  C Szabó; C C Wu; S S Gross; C Thiemermann; J R Vane
Journal:  Eur J Pharmacol       Date:  1993-11-30       Impact factor: 4.432

Review 5.  Pathogenetic mechanisms of septic shock.

Authors:  J E Parrillo
Journal:  N Engl J Med       Date:  1993-05-20       Impact factor: 91.245

Review 6.  Function and activation of NF-kappa B in the immune system.

Authors:  P A Baeuerle; T Henkel
Journal:  Annu Rev Immunol       Date:  1994       Impact factor: 28.527

7.  Assessment of splanchnic oxygenation by gastric tonometry in patients with acute circulatory failure.

Authors:  N Maynard; D Bihari; R Beale; M Smithies; G Baldock; R Mason; I McColl
Journal:  JAMA       Date:  1993-09-08       Impact factor: 56.272

8.  Pyrrolidine dithiocarbamate attenuates the development of organ failure induced by zymosan in mice.

Authors:  Salvatore Cuzzocrea; Antonietta Rossi; Barbara Pisano; Rosanna Di Paola; Tiziana Genovese; Nimesh S A Patel; Elisabetta Cuzzocrea; Angela Ianaro; Lidia Sautebin; Francesco Fulia; Prabal K Chatterjee; Achille P Caputi; Christoph Thiemermann
Journal:  Intensive Care Med       Date:  2003-07-17       Impact factor: 17.440

Review 9.  Tissue hypercarbic acidosis as a marker of acute circulatory failure (shock).

Authors:  Y Sato; M H Weil; W Tang
Journal:  Chest       Date:  1998-07       Impact factor: 9.410

10.  Improved survival of TNF-deficient mice during the zymosan-induced multiple organ dysfunction syndrome.

Authors:  Thomas J H Volman; Thijs Hendriks; Albert A J Verhofstad; Bart-Jan Kullberg; R Jan A Goris
Journal:  Shock       Date:  2002-06       Impact factor: 3.454

View more
  4 in total

Review 1.  Year in review in intensive care medicine, 2005. III. Nutrition, pediatric and neonatal critical care, and experimental.

Authors:  Peter Andrews; Elie Azoulay; Massimo Antonelli; Laurent Brochard; Christian Brun-Buisson; Geoffrey Dobb; Jean-Yves Fagon; Herwig Gerlach; Johan Groeneveld; Jordi Mancebo; Philipp Metnitz; Stefano Nava; Jerome Pugin; Michael Pinsky; Peter Radermacher; Christian Richard; Robert Tasker
Journal:  Intensive Care Med       Date:  2006-02-18       Impact factor: 17.440

2.  Crucial role of Rho-nuclear factor-kappaB axis in angiotensin II-induced renal injury.

Authors:  Yuri Ozawa; Hiroyuki Kobori
Journal:  Am J Physiol Renal Physiol       Date:  2007-04-04

3.  Effects of 15-deoxy-Delta12,14-prostaglandin-J2 during hyperdynamic porcine endotoxemia.

Authors:  Balázs Hauser; Jochen Kick; Zsolt Iványi; Pierre Asfar; Ulrich Ehrmann; Claus-Martin Muth; Maura Albicini; Ulrich Wachter; Josef Vogt; Michael Bauer; Uwe Bernd Brückner; Peter Radermacher; Hendrik Bracht
Journal:  Intensive Care Med       Date:  2006-03-14       Impact factor: 17.440

4.  Propofol attenuates LPS-induced tumor necrosis factor-α, interleukin-6 and nitric oxide expression in canine peripheral blood mononuclear cells possibly through down-regulation of nuclear factor (NF)-κB activation.

Authors:  Zengyang Pei; Jinqiu Wang
Journal:  J Vet Med Sci       Date:  2014-10-14       Impact factor: 1.267

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.